Calcipotriol and betamethasone dipropionate for the treatment of psoriasis: a 52-week study.
Psoriasis is a common skin disease affecting 1%-3% of the world's population with significant impacts on quality of life. There is a great need for therapies that are efficacious and safe, not only for the short-term, but also for long-term management. Dovobet/ Daivobet/ Taclonex is a product combining two molecules, calcipotriol and betamethasone dipropionate, that may offer psoriatic patients with an option for maintenance therapy. The efficacy and safety of this combined formulation when used over a 4-week period is well documented. A recent publication in the British Journal of Dermatology discusses the safety of this product when used for 52 weeks.
Toole
J W P
JW
Section of Dermatology, University of Manitoba, Winnipeg, MB, Canada.
D001623:Betamethasone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002117:Calcitriol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D015337:Multicenter Studies as Topic; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic
D004338:Drug Combinations; C517164:betamethasone dipropionate, calcipotriol drug combination; D001623:Betamethasone; D002117:Calcitriol